You are here

P&T® Journal contents for December 2005

Features

Blood Management
Mr. Alexander describes the importance of blood-conservation strategies, including the use of drugs, that can be beneficial during procedures such as transfusions and coronary artery bypass grafting.
Walter Alexander, MS
Meeting Highlights
Progress is being made in the way tumors are being targeted by agents such as lenalidomide, bortezomib, rituximab, and a variety of other novel chemotherapeutic regimens.
Marvin M. Goldenberg, PhD, RPh, MS
The Prescotts discuss hormonal replacement therapy; lasofoxifene for vaginal atrophy; testosterone for low libido; alendronate, transdermal estrogen, risedronate, and ibandronate for osteoporosis; and the transdermal oxybutynin patch for overactive bladder.
Lawrence M. Prescott, PhD, and Sharon L. Prescott
Continuing Education Credit
When switching patients from one selective serotonin reuptake inhibitor to another, health care providers need to consider several factors, namely, the pharmacokinetic profile of the current drug, the possibility of serotonin syndrome, and withdrawal symptoms.
Kristin Zerumsky, PharmD, Rae Ann Maxwell, RPh, PhD, and Nicole T. Ansani, PharmD

Departments

David Nash, MD, MBA, questions whether the widespread use of proton pump inhibitors is creating new problems, including the risk of Clostridium difficile infection.
David B. Nash, MD, MBA
Prescription: Washington
Stephen Barlas discusses problems with Medicare’s interim electronic prescribing standards, which exclude protocols that would have allowed PBMs and physicians to exchange important information.
Stephen Barlas
Medication Errors
Matthew Grissinger, RPh, FASCP, discusses the dangers of stray and intentional marks on prescription order forms.
Matthew Grissinger, RPh, FASCP
Drug Forecast
Dr. Small reviews an immediate-release formulation of the proton pump inhibitor omeprazole (Zegerid®) for the treatment of gastric acid–related disorders.
Ralph E. Small, PharmD
P&T presents the latest information about FDA approvals, drug indications, industry updates, and new devices.